pipette
ESEspañol

TET2-driven activation of AGO2 links epigenetic remodeling to myeloid commitment and leukemia

Aleksey Lazarenkov, Gemma Valcárcel, Alba Martínez-Moreno, Clara Berenguer, Anna V. López-Rubio, Mireia Obiols, Claudia Fontanet, Ana Barbă, Juan José Rodríguez‐Sevilla, Grégoire Stik, Irmela Jeremias, Pablo R. Menéndez, José Luis Sardina

Peer-reviewed journalReal-world use

In the authors' words

This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.

Main result
These findings uncover a TET2-AGO2 regulatory axis that integrates epigenetic remodeling, 3D genome reorganization, and leukemic fitness, and they highlight AGO2 as a potential biomarker and therapeutic target in myeloid leukemia.

Appeared: Sunday, October 25. Science Advances. Peer-reviewed journal.

DOI: 10.1126/sciadv.aee5701